Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC TrialEva Versteijne, Mustafa Suker, Karin Groothuis et al.|Journal of Clinical Oncology|2020Cited by 1.1k
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer GroupMarinde J. G. Bond, Johanneke H.M.J.V. Vestjens, Mike S.L. Liem et al.|The Lancet Oncology|2023Cited by 168
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver MetastasesMarinde J. G. Bond, Leonie J. Mekenkamp, Karen Bolhuis et al.|JAMA Oncology|2024Cited by 26
FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or <i>RAS</i>/<i>BRAFV600E-</i>mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.Cornelis J.A. Punt, Rutger‐Jan Swijnenburg, Marinde J. G. Bond et al.|Journal of Clinical Oncology|2022Cited by 14
LBA27 First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer GroupCornelis J.A. Punt, R-J. Swijnenburg, Marinde J. G. Bond et al.|Annals of Oncology|2023Cited by 10